/PBLA

PBLA Stock - Panbela Therapeutics, Inc.

Q: What is the analyst price target for PBLA?

Analyst price target information is not currently available for PBLA.

Q: What is PBLA's market cap?

Market capitalization information is not currently available for PBLA.

Healthcare|Biotechnology|OTC

$0.00+50.00%

+$0.00 (+50.00%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for PBLA

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2019

FY2020

FY2021

FY2022

FY2023

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.18

52W High$0.47

52W Low$0.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2023	FY2022	FY2021	FY2020	FY2019
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	$-25,647,000	$-35,731,000	$-10,010,000	$-5,754,000	$-4,322,000
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-51,294,000	$-34,093,000	$-10,010,000	$-5,754,000	$-4,322,000
Net Income	$-25,263,000	$-34,933,000	$-10,135,000	$-4,768,000	$-6,200,000
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-232429.55	$-40748.57	$-20773.70	$-14798.10	$-26103.83

Company Overview

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

Visit Website

Earnings History & Surprises

PBLA

Beat Rate

24%

Last 17 quarters

Avg Surprise

-14840.8%

EPS vs Estimate

Beats / Misses

4/13

Last 12 quarters

Latest EPS

$-1.48

Q4 2024

EPS Surprise History

Q1 23

-92100.3%

$-3411.41vs$-3.70

Q2 23

-32.7%

$-390.39vs$-294.29

Q3 23

-68.8%

$-159.00vs$-94.20

Q4 23

-30.6%

$-53.80vs$-41.20

Q1 24

-170.7%

$-65.90vs$-24.34

Q2 24

-85.4%

$-2.28vs$-1.23

Q3 24

+29.0%

$-1.47vs$-2.07

Q4 24

-22.3%

$-1.48vs$-1.21

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q4 2025	Nov 12, 2025	—	—	—	—
Q2 2025	May 29, 2025	—	—	—	—
Q1 2025	Mar 27, 2025	—	—	—	—
Q4 2024	Nov 14, 2024	$-1.21	$-1.48	-22.3%	✗ MISS
Q3 2024	Aug 13, 2024	$-2.07	$-1.47	+29.0%	✓ BEAT
Q2 2024	May 15, 2024	$-1.23	$-2.28	-85.4%	✗ MISS
Q1 2024	Mar 26, 2024	$-24.34	$-65.90	-170.7%	✗ MISS
Q4 2023	Nov 9, 2023	$-41.20	$-53.80	-30.6%	✗ MISS
Q3 2023	Aug 10, 2023	$-94.20	$-159.00	-68.8%	✗ MISS
Q2 2023	May 4, 2023	$-294.29	$-390.39	-32.7%	✗ MISS
Q1 2023	Mar 16, 2023	$-3.70	$-3411.41	-92100.3%	✗ MISS
Q4 2022	Nov 10, 2022	$-5525.52	$-5045.04	+8.7%	✓ BEAT
Q3 2022	Aug 15, 2022	$-5285.28	$-36276.27	-586.4%	✗ MISS
Q2 2022	May 12, 2022	$-6246.25	$-6486.49	-3.8%	✗ MISS
Q1 2022	Mar 24, 2022	$-4564.56	$-6246.25	-36.8%	✗ MISS
Q4 2021	Nov 10, 2021	$-6486.49	$-3843.84	+40.7%	✓ BEAT
Q3 2021	Aug 11, 2021	$-5525.52	$-5285.28	+4.3%	✓ BEAT
Q2 2021	May 12, 2021	$-4.40	$-5525.52	-125480.0%	✗ MISS
Q1 2021	Mar 25, 2021	$-6.40	$-2162.16	-33683.7%	✗ MISS
Q4 2020	Nov 12, 2020	$-4.80	$-8.40	-75.0%	✗ MISS

Frequently Asked Questions about PBLA

What is PBLA's current stock price?

Panbela Therapeutics, Inc. (PBLA) is currently trading at $0.00 per share. The stock has moved +50.00% today.

What is the analyst price target for PBLA?

No analyst price targets are currently available for this stock.

What sector is Panbela Therapeutics, Inc. in?

Panbela Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.

What is PBLA's market cap?

Panbela Therapeutics, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.

Does PBLA pay dividends?

No, Panbela Therapeutics, Inc. does not currently pay a dividend to shareholders.